PANDAR: a pivotal cancer-related long non-coding RNA in human cancers

IF 3.743 Q2 Biochemistry, Genetics and Molecular Biology

Molecular BioSystems Pub Date : 2017-09-26 DOI:10.1039/C7MB00414A

Jinglin Li, Zhenglong Li, Wangyang Zheng, Xinheng Li, Zhidong Wang, Yunfu Cui and Xingming Jiang

{"title":"PANDAR: a pivotal cancer-related long non-coding RNA in human cancers","authors":"Jinglin Li, Zhenglong Li, Wangyang Zheng, Xinheng Li, Zhidong Wang, Yunfu Cui and Xingming Jiang","doi":"10.1039/C7MB00414A","DOIUrl":null,"url":null,"abstract":"<p >Long non-coding RNAs (lncRNAs), non-protein-coding RNAs that are more than 200 nucleotides in length, have been demonstrated to play a vital role in the pathophysiology of human diseases, particularly in tumorigenesis and progression of cancers. Dysregulation of lncRNAs, which serve as either oncogenes or tumor suppressor genes, is involved in diverse cellular processes, such as proliferation, dedifferentiation, migration, invasion and anti-apoptosis. Promoter of CDKN1A antisense DNA damage-activated RNA (PANDAR), which was recently found to manifest aberrant expression in various malignancies including non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer and gastric cancer, is a novel cancer-related lncRNA. Deregulation of PANDAR contributes to tumorigenesis and progression of cancers, suggesting that PANDAR is likely to represent a viable biomarker and therapeutic target for human cancers. In this review, we summarize current evidence regarding the biological functions and mechanisms of PANDAR during tumor development.</p>","PeriodicalId":90,"journal":{"name":"Molecular BioSystems","volume":" 11","pages":" 2195-2201"},"PeriodicalIF":3.7430,"publicationDate":"2017-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1039/C7MB00414A","citationCount":"19","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular BioSystems","FirstCategoryId":"1085","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2017/mb/c7mb00414a","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}

引用次数: 19

Abstract

Long non-coding RNAs (lncRNAs), non-protein-coding RNAs that are more than 200 nucleotides in length, have been demonstrated to play a vital role in the pathophysiology of human diseases, particularly in tumorigenesis and progression of cancers. Dysregulation of lncRNAs, which serve as either oncogenes or tumor suppressor genes, is involved in diverse cellular processes, such as proliferation, dedifferentiation, migration, invasion and anti-apoptosis. Promoter of CDKN1A antisense DNA damage-activated RNA (PANDAR), which was recently found to manifest aberrant expression in various malignancies including non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer and gastric cancer, is a novel cancer-related lncRNA. Deregulation of PANDAR contributes to tumorigenesis and progression of cancers, suggesting that PANDAR is likely to represent a viable biomarker and therapeutic target for human cancers. In this review, we summarize current evidence regarding the biological functions and mechanisms of PANDAR during tumor development.

Abstract Image

查看原文本刊更多论文

PANDAR:人类癌症中关键的癌症相关长链非编码RNA

长链非编码rna (lncRNAs)是长度超过200个核苷酸的非蛋白质编码rna，已被证明在人类疾病的病理生理学中起着至关重要的作用，特别是在肿瘤发生和癌症进展中。lncRNAs作为癌基因或抑癌基因，其失调参与多种细胞过程，如增殖、去分化、迁移、侵袭和抗凋亡。CDKN1A反义DNA损伤激活RNA (PANDAR)启动子是一种新型的癌症相关lncRNA，近年来在非小细胞肺癌、肝细胞癌、结直肠癌和胃癌等多种恶性肿瘤中发现异常表达。对PANDAR的抑制有助于肿瘤的发生和癌症的进展，这表明PANDAR可能是一种可行的生物标志物和人类癌症的治疗靶点。在这篇综述中，我们总结了目前关于PANDAR在肿瘤发展中的生物学功能和机制的证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular BioSystems 生物-生化与分子生物学

CiteScore

2.94

自引率

0.00%

发文量

审稿时长

2.6 months

期刊介绍： Molecular Omics publishes molecular level experimental and bioinformatics research in the -omics sciences, including genomics, proteomics, transcriptomics and metabolomics. We will also welcome multidisciplinary papers presenting studies combining different types of omics, or the interface of omics and other fields such as systems biology or chemical biology.